| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Moleculin Biotech (NASDAQ:MBRX) through any online brokerage.
Other companies in Moleculin Biotech’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Moleculin Biotech has a consensus price target of $100.75.
The stock price for Moleculin Biotech (NASDAQ: MBRX) is $0.4761 last updated October 2, 2026 at 6:14 PM EDT.
There are no upcoming dividends for Moleculin Biotech.
Moleculin Biotech does not have any upcoming earnings scheduled.
There is no upcoming split for Moleculin Biotech.
Moleculin Biotech is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
